Skip to content
About the CRC
Vision & Goals
Consortium & Structure
Team
Research
Cell-Intrinsic Factors (Area A)
A01: Functions of the dynamic ribosomal epitranscriptome in shaping myeloid plasticity
A02: Mitochondrial RNA modification-driven metabolic plasticity in leukemic stem cells and drug resistance
A03: Targeting metabolic plasticity to overcome chemotherapyresistance in acute myeloid leukemia
A04: Loss of Y chromosome in acute myeloid leukemia drives tumorcell plasticity and drug resistance
A05: Deciphering plasticity of relapse-driving, chemo-resistant LSC states in DNMT3Amut NPM1mut AML
A06: Plastic growth behavior of patients’ AML in vivo: Releasing dormant cells from their protective niche
A07: Myeloid antigen plasticity as critical determinant of AML immune surveillance
Cell-Extrinsic Factors (Area B)
B01: Predicting response to venetoclax/azacitidine in AML by determining cytologic variability in AML blasts with generative AI image analysis combined with single-celltranscriptomics
B02: Investigation into the plastic state of dormancy in JAK2-V617F driven myeloproliferative neoplasms (MPNs) and secondary acute myeloid leukemias (sAMLs)
B03: Multi-modal proteomics to understand and overcome nicherelatedadaptive drug-resistance mechanisms in FLT3-mutated AML
B04: Dissecting mechanisms of immunotherapy-induced plasticity in AML through multi-omics and genome-wide CRISPR screens
B05: Characterizing lineage plasticity of KMT2A/AFF1-rearranged acute leukemia under therapeutic pressure from CAR T cells
B06: Leukemia cell plasticity and NK cell activity as determinants of relapse in AML
B07: Single cell multi-omics to unravel niche plasticity in AML therapy resistance
B08: Spatial and epigenetic plasticity during leukemia development
B09: Inflammation-driven plasticity in disease progression in Advanced Systemic Mastocytosis
B10: Cellular plasticity driven by innate immune activation in DDX41-mediated myeloid malignancies
B11: Deciphering and therapeutically exploiting immunerelated cellular plasticity during allogeneic stem celltransplantation in myeloid malignancies
Core Projects
INF: Data Management, Information Infrastructure, and Application
Z01: Central administration
Z02: Clinically annotated primary tumor cells and mouse clinics for patient-derived xenograft (PDX) models
Z03: Proteomic and single-cell transcriptomic landscapes of cellular plasticity in myeloid malignancies
Publications
Events
Events Archive
News
Contact
About the CRC
Vision & Goals
Consortium & Structure
Team
Research
Cell-Intrinsic Factors (Area A)
A01: Functions of the dynamic ribosomal epitranscriptome in shaping myeloid plasticity
A02: Mitochondrial RNA modification-driven metabolic plasticity in leukemic stem cells and drug resistance
A03: Targeting metabolic plasticity to overcome chemotherapyresistance in acute myeloid leukemia
A04: Loss of Y chromosome in acute myeloid leukemia drives tumorcell plasticity and drug resistance
A05: Deciphering plasticity of relapse-driving, chemo-resistant LSC states in DNMT3Amut NPM1mut AML
A06: Plastic growth behavior of patients’ AML in vivo: Releasing dormant cells from their protective niche
A07: Myeloid antigen plasticity as critical determinant of AML immune surveillance
Cell-Extrinsic Factors (Area B)
B01: Predicting response to venetoclax/azacitidine in AML by determining cytologic variability in AML blasts with generative AI image analysis combined with single-celltranscriptomics
B02: Investigation into the plastic state of dormancy in JAK2-V617F driven myeloproliferative neoplasms (MPNs) and secondary acute myeloid leukemias (sAMLs)
B03: Multi-modal proteomics to understand and overcome nicherelatedadaptive drug-resistance mechanisms in FLT3-mutated AML
B04: Dissecting mechanisms of immunotherapy-induced plasticity in AML through multi-omics and genome-wide CRISPR screens
B05: Characterizing lineage plasticity of KMT2A/AFF1-rearranged acute leukemia under therapeutic pressure from CAR T cells
B06: Leukemia cell plasticity and NK cell activity as determinants of relapse in AML
B07: Single cell multi-omics to unravel niche plasticity in AML therapy resistance
B08: Spatial and epigenetic plasticity during leukemia development
B09: Inflammation-driven plasticity in disease progression in Advanced Systemic Mastocytosis
B10: Cellular plasticity driven by innate immune activation in DDX41-mediated myeloid malignancies
B11: Deciphering and therapeutically exploiting immunerelated cellular plasticity during allogeneic stem celltransplantation in myeloid malignancies
Core Projects
INF: Data Management, Information Infrastructure, and Application
Z01: Central administration
Z02: Clinically annotated primary tumor cells and mouse clinics for patient-derived xenograft (PDX) models
Z03: Proteomic and single-cell transcriptomic landscapes of cellular plasticity in myeloid malignancies
Publications
Events
Events Archive
News
Contact
Menu
Emilija Marinkovic, Ph.D.
Postdoc
Institute for Immunology, University Hospital Heidelberg
Research
Contact
WordPress Cookie Notice by Real Cookie Banner
